Akeso Biopharma Inc. filed to list its shares on the Hong Kong Stock Exchange.

The Guangdong, China-based privately held life sciences tools and services company acts as a contract research organization for pharmaceutical companies that focus on developing antibody drugs and protein-based drugs.

Akeso Biopharma previously announced that it received about $150 million in funding from existing and new investors.

Moreover, it entered into a joint venture in June with privately held pharmaceutical Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd. to develop and commercialize a PD-1 antibody called AK105.